Did anyone else notice that Dr Monil Shah, having been appointed as Chief Business Officer (CBO) and a member of the Company's executive management team in 2021 is now appearing on the executive team slide as a consultant. The results are clear for all of us in terms of commercial outcomes so far, however, the question is: Is he being gently 'disappeared' or does this provide greater flexibility? I asked this question in the webinar as soon as I saw it but am not surprised that it hasn't been addressed.
Ann: Imugene Webinar - Azer-cel Trial Update, page-62
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
-0.003(4.84%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 6.1¢ | 6.3¢ | 5.8¢ | $2.926M | 48.68M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 1489666 | 5.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.9¢ | 1250588 | 5 |
View Market Depth
| Last trade - 16.10pm 04/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |